The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...
High serum type I interferon (IFN) scores, measured through six chemokines, correlated with poorer lung function and health-related quality of life in patients with diffuse cutaneous systemic ...
The severity and extent of skin fibrosis in systemic sclerosis (SSc) is a useful early indictor of overall disease severity, but the modified Rodnan skin score (mRss)—which assesses skin fibrosis by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results